XSHE
300406
Market cap1.05bUSD
Oct 09, Last price
12.14CNY
1D
1.68%
1Q
8.10%
Jan 2017
-44.79%
IPO
114.11%
Name
Beijing Strong Biotechnologies Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Strong Biotechnologies, Inc. operates as a supplier of in-vitro diagnostic (IVD) solutions, encompassing both products and associated services, for markets within the People's Republic of China and globally. The firm's comprehensive product line includes offerings for clinical biochemistry, such as diagnostic reagents and sophisticated automated analyzers. Additionally, it provides coagulation-related items, including necessary reagents and automated analysis instrumentation. Furthermore, its serology division delivers blood type testing cards and advanced automated systems for blood grouping. This enterprise was established in 2001 and has its corporate headquarters situated in Beijing, China.
Key people
Hongjun Liang
Vice Chairman of the Board, General Manager · since 2023
Wei Liu
Chief Financial Officer · since 2007
Qixin Lin
Deputy General Manager · since 2023
Qinghai Yang
Deputy General Manager · since 2023
Yi Zhang
Deputy General Manager · since 2008
Jianmin Wang
Secretary of the Board · since 2015
Xi Liu
Director · since 2023
Aiping Luo
Director · since 2001
Xiaolin Sun
Director · since 2001
Xiaoya Wang
Director · since 2023
Zuojun Zou
Chairman of the Board · since 2011
Independent Director · since 2020
Jianping Yang
Independent Director · since 2023
Jun Ye
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||